Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 2/20 | 0.34 |
| ▸ | PRF1 | P14222 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14734800 | 0.91 | PRKCI (0.36) | POLQTDP2PRF1MAPKAPK2GSK3B | |
| SCHEMBL2592055 | 0.89 | POLQ (0.35) | POLQTDP2PRF1MAPKAPK2GSK3B | |
| SCHEMBL14734754 | 0.89 | GSK3B (0.38) | POLQTDP2PRF1MAPKAPK2GSK3B | |
| SCHEMBL2591973 | 0.88 | POLQ (0.35) | POLQTDP2PRF1MAPKAPK2GSK3B | |
| SCHEMBL2584838 | 0.88 | POLQ (0.37) | POLQTDP2PRF1MAPKAPK2GSK3B | |
| SCHEMBL2584358 | 0.88 | POLQ (0.39) | POLQTDP2PRF1MAPKAPK2GSK3B | |
| SCHEMBL14734824 | 0.86 | POLQ (0.36) | POLQTDP2PRF1MAPKAPK2GSK3B | |
| SCHEMBL14734803 | 0.86 | GSK3B (0.36) | POLQTDP2PRF1MAPKAPK2GSK3B | |
| SCHEMBL14736839 | 0.86 | HSD17B1 (0.38) | ADORA1 | |
| SCHEMBL14736679 | 0.85 | POLQ (0.36) | POLQTDP2PRF1MAPKAPK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563770-B1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-03-23 | — | — | EP | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| EP-2563770-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134468-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE4A | POLQ 1717/4885TDP2 54/4885PRF1 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.